Asia-Pacific Health Industries 2016: Keeping You Up-To-Date With The Latest Developments

Asia-Pacific Health Industries Newsletter 2016: Keeping You Up-To-Date With The Latest Developments

by PricewaterhouseCoopers
In recent years there has been a shift in the nature of healthcare, i.e., from reactive to preventative. An integral component of this shift has been the emergence of personalised medicine. Personalised medicine is a model that segments patients by risk of developing a specific disease, based on their genetic profile. This includes, molecular diagnosis and use of biomarkers to segment populations. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals July 2016

Table 1-2 Pharmaceuticals July 2016

by KPMG
The number of completed deals remained high in both sectors in HY1 2016. While total deal value for pharmaceuticals decreased, chemicals witnessed a 40% increase in HY1 2016 versus HY1 2015. Pharmaceutical M&A was impacted by stock market volatility, while new US regulatory rules struck down the $160 billion Pfizer-Allergan merger. Oncology and dermatology were key areas of interest for big pharma, who were especially keen on acquiring biotech assets. […] Read more

Biotechnology Report 2016: Beyond Borders – Returning To Earth

Figure 1 US and European biotechnology centers at a glance 2015

by Ernst & Young
In 2016, the biopharma world is on somewhat unfamiliar footing. After five years of market cap gains and increasingly buoyant capital markets, biotech’s fortunes peaked in 2015. The biotech industry’s cumulative market cap has dropped precipitously over the past nine months. As this year’s Beyond borders report describes, although new records were set in cumulative revenue, net income and R&D spend, growth rates in all three categories have slowed. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

by KPMG
While the number of completed pharma deals were slightly higher in Q1 2016 versus Q1 2015, deal value was far lower in the absence of any >$10 billion completions. Only one deal exceeded $5 billion in Q1 2016 (versus 8 in Q1 2015). Specialization continues to be a driving force in Q1 2016, especially in sectors such as OTC, rare diseases and oncology. Declines in transaction values were also witnessed in chemicals. Downstream specialty chemicals was the leading focus area, notably in applications, resins and agrochemicals. […] Read more

Pfizer, Allergan deal dead, what could be next?

Pfizer Allergan Merger

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Pfizer, Allergan deal dead, what could be next?

Pfizer Allergan Merger

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Pfizer, Allergan deal dead, what could be next?

Pfizer Allergan Merger

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Approach To The Issues Of Leadership In The Processes Of Companies’ Acquisitions

Table 2 Approach to the issues of leadership in the process of acquisition in the examined pharmaceutical companies

by Elsevier Ltd.
This paper presents the results of the research concerning five transactions in the pharmaceutical sector. The research aim was to diagnose an approach to the issues of leadership, which in the literature is often treated as a key success factor in the processes of acquisitions. The research showed that in the analyzed pharmaceutical companies which participated in the research little attention was paid to the issues of leadership. […] Read more

Die größten Pharmaunternehmen der Welt

Figure 1 Analysierte Unternehmen

by Ernst & Young
Eine Analyse wichtiger Finanzkennzahlen für die Geschäftsjahre 2012, 2013 und 2014. Analysiert wurden die Pharma-Umsätze der 20 weltweit umsatzstärksten börsennotierten Pharma-Unternehmen. Branchenfremde Aktivitäten sind nicht in die Analyse eingeflossen. Quellen: Geschäftsberichte, Pressemitteilungen der Unternehmen, SEC-Filings. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!